Suspension of trading

NeuBase Therapeutics, Inc. Stock

O7P

US64132K2015

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 09:03:16 13/05/2024 +03			5-day change	1st Jan Change
0.3406 ^EUR	-0.58%		-.--%	-

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.11M 1.05M 957K 1.79M 122M 1.8M 12.55M 4.85M 62.19M 4.8M 4.69M 199M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.11M 1.05M 957K 1.79M 122M 1.8M 12.55M 4.85M 62.19M 4.8M 4.69M 199M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news: NeuBase Therapeutics, Inc.

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
27/06/24	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
29/05/24	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	01/11/2021

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	04/01/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-0.58%	-.--%	-.--%	-71.38%	1.39M
LONZA GROUP AG	+1.23%	+1.87%	-0.15%	+9.57%	45.91B
IQVIA HOLDINGS INC.	+0.23%	+4.72%	+44.32%	+27.27%	44.25B
REVOLUTION MEDICINES, INC.	+0.52%	-3.15%	+349.53%	+520.09%	41.99B
BEONE MEDICINES AG	+1.55%	+3.41%	+6.40%	+76.45%	39.58B
CELLTRION, INC.	+1.75%	-0.28%	+12.42%	+41.11%	31.08B
MEDPACE HOLDINGS, INC.	-0.20%	+5.49%	+23.57%	+119.72%	17.21B
ASCENDIS PHARMA A/S	-3.49%	-8.49%	-	-	16.27B
EUROFINS SCIENTIFIC SE	+2.92%	+8.40%	+22.46%	+38.87%	14.96B
ICON PUBLIC LIMITED COMPANY	-2.45%	+2.41%	-3.16%	-35.16%	13.42B
Average	+0.15%	+0.28%	+50.60%	+80.73%	26.47B
Weighted average by Cap.	+0.58%	+0.33%	+72.35%	+120.61%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company